Ligand Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

26.09.14	Ligand Earns Milestone Payment Triggered by EU Approval of Merck’s Captisol-enabled NOXAFIL® (posaconazole) Concentrate for Solution for Infusion (Businesswire)
15.08.14	LGND Does A Deal, Q2 Revenue A Bitter Pill For BGMedicine, CRMD On Watch (RTTNews)
23.06.14	Ligand to Participate in ROTH Capital Partners’ Healthcare Corporate Access Day in London (Businesswire)
13.06.14	Eltrombopag Meets Primary Endpoint In Phase 3 PETIT2 Study - Quick Facts (RTTNews)
23.04.14	Spectrum Pharma's Trial Of Captisol-Enabled Melphalan Meets Primary Endpoint (RTTNews)
11.02.14	Ligand Pharma Q4 Profit Up (RTTNews)
03.02.14	Ligand Partner GlaxoSmithKline Gains FDA Breakthrough Therapy Designation for Promacta®/Revolade® for Severe Aplastic Anemia (Businesswire)
09.12.13	Ligand Posts Positive Preclinical Data On Small-Molecule G-CSF Receptor Agonist (RTTNews)
07.10.13	Ligand Pharma: FDA Oks IND Application For Glucagon Receptor Antagonist Program (RTTNews)
02.10.13	Regulatory Approval, New Appointments, Stock Price Movements, and Other Announcements - Research Report on Pfizer, Warner Chilcott, Rockwell Medical, InterMune, and Ligand (PR Newswire)
14.08.13	Ligand Signs Deal With CURx Pharma For Captisol-Enabled Topiramate Injection (RTTNews)
29.07.13	New License Agreements and Financial Results Release - Research Report on Elan, Waters, InterMune, Spectranetics, and Ligand (PR Newswire)
26.07.13	Ligand Partner GSK Receives Positive CHMP Opinion For Revolade (RTTNews)
26.07.13	Ligand Partner GlaxoSmithKline Receives Positive CHMP Opinion for REVOLADE™ in Thrombocytopenia Associated with Chronic Hepatitis C Infection (Businesswire)
26.07.13	Ligand Gets Orphan Designation For Captisol-Enabled Topiramate Injection (RTTNews)
19.07.12	Ligand Partner Pfizer Announces European Medicines Agency Accepts Regulatory Submission for Bazedoxifene/Conjugated Estrogens for the Treatment of Symptoms Associated with Menopause and Osteoporosis (Businesswire)
11.06.12	Ligand Announces Positive Preclinical Data on LGD-6972 at the American Diabetes Association’s 72nd Scientific Sessions (Businesswire)
14.05.12	Ligand to Present at the Jefferies 2011 Global Healthcare Conference on June 4 (Businesswire)
07.05.12	Ligand to Present at the Bank of America Merrill Lynch 2012 Health Care Conference on May 17 (Businesswire)
02.05.12	Ligand Pharmaceuticals Reports First Quarter Results (Businesswire)
16.04.12	Ligand to Report First Quarter Results on May 2nd (Businesswire)
05.03.12	Ligand to Present at the 24th Annual Roth Conference on March 12 (Businesswire)
21.02.12	Ligand to Present at the Citi Global Health Care Conference on February 28th (Businesswire)
21.02.12	Ligand Licenses DARA Program to Retrophin (Businesswire)
09.02.12	Ligand to Present at the BIO CEO and Investor Conference on February 13 (Businesswire)
07.02.12	Ligand Reports Fourth Quarter and Full Year 2011 Financial Results (Businesswire)
07.02.12	Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development (Businesswire)
02.02.12	Ligand Presents Full Data from Successful Phase II Trial of Captisol-Enabled®, Propylene Glycol-Free Melphalan at the BMT Tandem Meetings (Businesswire)
01.02.12	Ligand to Report Fourth Quarter Results on February 7 (Businesswire)
04.01.12	Ligand to Present at the Biotech Showcase Conference on January 10th (Businesswire)
21.12.11	Ligand Enters into Platform Captisol® License and Supply Agreements with Lilly (Businesswire)
12.12.11	Ligand Announces Positive Preclinical Data on Small-Molecule GCSF Receptor Agonist at the 53rd Annual Meeting of the American Society of Hematology (Businesswire)
12.12.11	CSC Board Declares Quarterly Cash Dividend (Businesswire)
12.12.11	Artio Global Investors Inc. Announces November Month-End Assets Under Management (Businesswire)
07.12.11	Ligand to Present at the Oppenheimer Healthcare Conference on December 14 (Businesswire)
08.11.11	Ligand Pharmaceuticals Announces Third Quarter Results (Businesswire)
08.11.11	Globecomm Reports Fiscal 2012 First Quarter Financial Results (Businesswire)
08.11.11	Xerium Technologies Reports Third Quarter Results (Businesswire)
07.11.11	Ligand Announces Positive Preclinical Data on IRAK4 Program at the 2011 American College of Rheumatology Annual Scientific Meeting (Businesswire)
07.11.11	Save-the-Date: Ligand Hosting Promacta Panel Discussion on November 7 (Businesswire)
16.05.05	Investigators Present Detailed Targretin Lung Cancer Data from SPIRIT (Businesswire)
30.03.05	Investigators Present Initial Results of Two AVINZA Trials at APS; Fir (Businesswire)
28.03.05	Targretin Fails to Meet Primary or Secondary Endpoints in Pivotal Tria (Businesswire)
17.03.05	Ligand Announces Delay in Filing of 10-K (Businesswire)
17.03.05	Ligand Announces Conference Call (Businesswire)
14.03.05	Ligand and SRI/Burnham Agree to Settle Patent Interference on Targreti (Businesswire)
19.02.05	Ligand Presentation at BIO's CEO and Investor Conference to be Web Ca (Businesswire)
17.02.05	Ligand to Present at the Roth Capital Partners 17th Annual Growth Stoc (Businesswire)
08.02.05	Ligand Earns $1.0 Million Milestone Payment as GlaxoSmithKline Commenc (Businesswire)
03.02.05	Pfizer Submits SNDA to Expand Potential Market for Lasofoxifene; Trigg (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’282.00	1.18 %	K V
Kuehne+Nagel Int	203.50	0.44 %	K V
Lonza Grp	543.20	0.33 %	K V
Holcim	89.12	0.29 %	K V
Alcon	76.50	0.24 %	K V
Swisscom	502.50	-0.89 %	K V
Sika	223.50	-1.19 %	K V
Nestle	73.78	-1.91 %	K V
Swiss Re	129.40	-1.93 %	K V
Givaudan	3’977.00	-2.07 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Ligand Pharmaceuticals Inc

Aktien Top/Flop

Meistgelesene Nachrichten